Background/Aim. Reactive thrombocytosis, as a paraneoplastic syndrome, is often
Introduction
Colorectal cancer (CRC) is among the leading causes of mortality and morbidity throughout the world 1 . Overall, CRC ranks third in terms of incidence but second in terms of mortality 2 . The incidence of colorectal cancer is increasing due to ageing and unhealthy life style 3 . Although the distribution of CRC varies widely (worldwide incidence and mortality, 10.2 % and 9.2% of all cancers, respectively), more than two-thirds of all cases and more than half of all deaths happen in countries with high human development index (HDI) 2 . Frequently consumption of red or processed meat, alcohol drinks, and body fatness increase the risk of CRC, whereas physical activity is protective [4] [5] [6] .
Thrombocytosis, a paraneoplastic syndrome, frequently accompanies cancer growth and metastatic dissemination, and is observed in as many as 10-57% of cancer patients 7, 8 . A pathogenic feedback loop may be operative between platelets and tumor cells, with reciprocal interactions between tumor growth/metastasis and thrombocytosis/platelet activation 7 . A variety of tumor-related humoral factors and cytokines such as granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF), thrombopoietin (TPO) 8 , IL-1, IL-3, IL-6, IL-11 influence thrombopoiesis in cancer and contribute to tumor-stimulated thrombopoiesis 8, 9 .
Several recent studies have reported that thrombocytosis may be associated with the poor prognosis of CRC 10 . Thrombocytosis is associated with shorter overall, disease-free and cancer-specific survival. Overall survival is reduced in patients with thrombocytosis regardless of their clinical tumor stage, and ethnicity. Also, thrombocytosis is significantly related to female patients, colon tumor location, T3-4 stage, lymph node positivity, metastasis, undifferentiated histology and lymphatic involvement 11, 12 .
Interleukin (IL)-33, an IL-1 family member, plays an essential role in the regulation of immune response after cellular stress or damage 13, 14 . Recent study revealed that IL-33 by biding to its receptor ST2 inhibits host anti-tumor immunity, remodels tumor stroma and enhances angiogenesis, thereby promoting the development of CRC 15 . Patients with metastatic CRC, with higher expression of IL-33 in cancer tissues were significantly associated with poorer survival 14, 16 
Measurement of cytokine concentration in serum
From each patient one blood sample in the volume of 10 ml was taken preoperatively, before surgery. Serum was separated by centrifugation and stored at -80 °C until testing.
The test was performed using commercial sensitive enzyme-linked immunosorbent assay 
Results
Fifty nine adult patients (n=59) with diagnosed CRC were recruited in this study.
Patients with diagnosed CRC were divided in two groups according to the number of platelets. The first group includes 35 CRC patients with the number of platelets < 450×10 9 /L (group without thrombocytosis), while the second group included 24 CRC patients with the number of platelets ≥ 450×10 9 /L 18, 19 (group with thrombocytosis).
Clinical and pathologic characteristics of these patients are presented in Table 1 .
Table 1
There were no differences in age or gender distribution between two groups.
Concentrations of tumor markers AFP, CEA and CA 19-9 were significantly higher in CRC patients with thrombocytosis compared to CRC patients without thrombocytosis (Table 1) .
Evaluation of nuclear grade of CRC was also made in patients with the presence or absence of thrombocytosis. Nuclear grade was based on evaluation of the size and shape of the nucleus in cells of colorectal cancer and the percentage of tumor cells that are in the process of dividing or growing 20 . Results revealed that CRC patients with thrombocytosis had significantly higher nuclear grade of colorectal cancer in comparison to patients with normal number of platelets (p=0.002; Figure 1A) . Next, CRC patients with/without thrombocytosis were analyzed regarded detection of lymph and blood vessels invasion. 
Figure 4 Discussion
In the present study, we have showed that CRC patients with diagnosed thrombocytosis had significantly higher nuclear grade compared to CRC patients with normal number of platelets ( Figure 1 ). Significantly higher percentage of CRC patients with thrombocytosis had detectable metastatic lesions in lung and liver and peritoneal carcinomatosis, as well as blood and lymph vessels invasion compared to CRC patients without thrombocytosis ( Figure 1 ). Higher concentrations of tumor markers AFP, CEA, CA 19-9 were detected in CRC patients with diagnosed thrombocytosis (Table 1 ). In line with the revelation of previous studies that increased concentrations of tumor markers in patients with CRC indicate on more aggressive type of cancer and can be treated as poor prognostic factor, presented data indicate on more severe form of CRC in patients with thrombocytosis 21 .
Reactive thrombocytosis is an elevated platelet count (≥ 450×10 9 /L) develops secondary to another disorder 19 . Previous studies investigated relation between cancer and thrombocytosis 10-12, 22-24 . Sasaki et al. have shown that cancer-specific survival of CRC patients with thrombocytosis was significantly shorter compared to CRC patients without diagnosed thrombocytosis 22 . Moreover, thrombocytosis indicates adverse prognosis in CRC and also may serve as clinically useful, cost-effective, noninvasive marker to facilitate risk assessment and guide postoperative management 11, 12 . The platelet count is also treated as valuable prognostic marker for the survival in patients with metastasis of colorectal cancer 23 . Furthermore, pretreatment hematologic abnormalities, such as anemia and thrombocytosis, can be also considered as useful prognostic markers in patients with colorectal cancer 24 . In line with these studies, presented data implicate on severe and more progressive form of colorectal cancer in patients with diagnosed thrombocytosis.
Several factors such as iron deficiency, acute infection and chronic inflammatory disorders can be causes of reactive thrombocytosis 19 . Lately, cancer is more often associated with paraneoplastic thrombocytosis 7 . A variety of tumor-related humoral factors and cytokines influence thrombopoiesis in patients with tumor and contribute to tumorstimulated thrombopoiesis 8, 9 . In order to investigate potential role of soluble molecules on thrombocytosis development, we have further analyzed systemic concentrations of cytokines of interest. IL-1 is potent cytokine involved in variety of pro-inflammatory processes, but also in tumorigenesis and tumor progression 25 . Besides direct stimulating effect on tumor cell proliferation, it has also been shown that colon cancer cell-derived IL-1α may upregulate angiogenesis by modulating stromal cells within the tumor microenvironment 15 . In this study, significantly higher systemic level of IL-1 was measured in CRC patients with diagnosed thrombocytosis compared to CRC patients with normal number of platelets (Figure 2 ). Previous studies investigate the importance of IL-1 in thrombocytopoiesis [26] [27] [28] . Yang et al. revealed stimulative effect of IL-1β on megakaryocyte colony forming units production. Moreover, they confirmed that megakaryocytic cells have IL-1 receptors on their surface 26 . The other study has shown that a single dose of IL-1 was able to stimulate an increase in platelet production for 3 weeks. 27 . Also, administration of recombinant human IL-1β to C57B1/6 male mice consequently induced a remarkable thrombocytosis, about 2.3 times higher in IL-1β treated mice than in control mice 28 . These results are in line with our finding, suggesting on important role of IL-1 in thrombocytosis development.
IL-33, member of IL-1 family is mostly expressed by mucosal epithelial cells 29 .
Previous studies confirmed important role of IL-33 in CRC pathogenesis 13, 14 . It is known that IL-33 activates core stem cell genes, recruits macrophages into the cancer microenvironment and stimulates them to produce prostaglandin E2, which all promote carcinogenesis of CRC and metastasis of cancers 16, 30 . To our knowledge, this is the first study describing significant increment of IL-33 in sera of CRC patients with diagnosed thrombocytosis compared to CRC patients without thrombocytosis (Figure 2 ). In line with our result are different animal and clinical studies suggesting on importance of IL-33 in pathogenesis of thrombocytosis. Talabot et al. described that CMV/IL33 mice with IL-33 overexpression, characterized as increased local or systemic levels of pro-inflammatory mediators such as IL-1b, Cxcl-1, G-CSF, and IL-6, also suffer from anemia, thrombocytosis, and dysregulation of myelopoiesis 31 . The other study has shown that ST2, membrane receptor for IL-33 is expressed in bone marrow mainly on endothelial, mesenchymal, and early myeloid cells. Activation of IL-33/ST2 signaling pathway on these cells stimulates production of different soluble molecules that further promote development and proliferation of myeloid cells 32 . Previous studies have confirmed that thrombocytosis correlates with a shorter overall survival (OS) and poorer disease free survival (DFS) 33, 34 .
Except platelet number, other platelet-associated indicators, such as plateletcrit (PCT), mean platelet volume (MPV) and platelet distribution width (PDW), may also correlate with poorer OS of CRC patient and can be used as potentional prognostic factors 35 . To our knowledge, some studies revealed that development and progression of CRC is associated with alterations in serum IL-1 level but it`s significance is not well defined 36, 37 
Figure 5
This proposed mechanism is supported by analysis of Receiver Operating Characteristic (ROC) curves of IL-33 and IL-1 revealed that these cytokines could be used as posible markers of paraneoplastic thrombocytosis in CRC patients (Figure 4 ).
Conclusion
Presented data revealed that IL-1 and IL-33 are significantly correlated to high thrombocyte number in patients with more aggressive CRC.
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